4070 Stock Chart & Stats
€28.40
€0.00(0.00%)
At close: 4:00 PM EDT
€28.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.00 - €34.60
Previous CloseN/A
Volume0.00
Average Volume (3M)54.00
Market Cap
€776.37M
Enterprise Value-€38.00
Total Cash (Recent Filing)€186.44M
Total Debt (Recent Filing)€592.00K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 10, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-141.65
Shares Outstanding25,840,425
10 Day Avg. Volume16
30 Day Avg. Volume54
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€50.29Price Target Upside77.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-13.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Faeth greater financial flexibility while it advances its development pipeline. Limited debt reduces solvency and interest-burden risk, allowing more capital to be directed toward research and clinical progress rather than debt servicing.
Scientific GovernanceAdding a recognized cancer biologist and experienced public-company director strengthens scientific oversight and governance. Her expertise in tumor biology and metabolic dependencies is directly relevant to Faeth’s therapeutic focus and may improve strategic decision-making.
Performance-linked IncentivesPerformance-based equity awards tie employee and leadership compensation to a demanding long-term outcome rather than routine service alone. This can improve incentive alignment, focus management on value creation, and support disciplined execution of the company’s strategy.
Bears Say
No Commercial RevenueThe absence of meaningful revenue shows that Faeth remains a development-stage biotechnology company without a self-sustaining commercial model. Persistent large losses increase dependence on future financing and leave business progress reliant on successful pipeline advancement.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not funding its activities internally. Even with recent improvement, continued cash consumption can require additional capital and may constrain the pace or scope of pipeline development if losses persist.
Financing And Dilution RiskThe equity program provides an important funding tool for a cash-burning biotech, but issuing shares can dilute existing ownership. The substantial preferred-share conversion and expanded common-share base reinforce the risk that future financing needs may reduce per-share participation.
Faeth Therapeutics News
4070 FAQ
What was Faeth Therapeutics’s price range in the past 12 months?
Faeth Therapeutics lowest stock price was €6.00 and its highest was €34.60 in the past 12 months.
What is Faeth Therapeutics’s market cap?
Faeth Therapeutics’s market cap is €776.37M.
When is Faeth Therapeutics’s upcoming earnings report date?
Faeth Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 50 days.
How were Faeth Therapeutics’s earnings last quarter?
Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -€2.451 earnings per share for the quarter, missing the consensus estimate of -€2.275 by -€0.176.
Is Faeth Therapeutics overvalued?
According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.
Does Faeth Therapeutics pay dividends?
Faeth Therapeutics does not currently pay dividends.
What is Faeth Therapeutics’s EPS estimate?
Faeth Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Faeth Therapeutics have?
Faeth Therapeutics has 25,840,425 shares outstanding.
What happened to Faeth Therapeutics’s price movement after its last earnings report?
Faeth Therapeutics reported an EPS of -€2.451 in its last earnings report, missing expectations of -€2.275. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Faeth Therapeutics?
Currently, no hedge funds are holding shares in DE:4070
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faeth Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€50.29 (77.08% Upside)
€50.29 (77.08% Upside)
Blogger Sentiment
Bullish
DE:4070 Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth €1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
270.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
495.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
4070 Stock 12 Month Forecast
Average Price Target
€50.29
▲(77.08% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―